STAT January 13, 2025
The deal includes Caplyta, a medicine that could soon be approved in larger indications
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its...